Common Variable Immunodeficiency (CVID)
A primary immunodeficiency marked by low antibody levels and recurrent infections, with treatment options ranging from immunoglobulin replacement to targeted management of associated complications.
- Specialist Immunology Review
- Immunoglobulin Therapy Access
- Complication Screening Support
- Most Diagnosed In
- Adults 20sโ40s
- Key Feature
- Low IgG, IgA, IgM
- Often Underdiagnosed By
- 5โ9 Years
- Advanced Therapies
- IgG Replacement, Targeted Biologics
Condition Overview
Common Variable Immunodeficiency (CVID) is the most frequently diagnosed primary immunodeficiency affecting antibody production. It is characterized by low levels of immunoglobulins, especially IgG, along with reduced IgA and/or IgM, and a diminished ability to make protective antibodies after infection or vaccination.
CVID can present at any age but is most often recognized in the second or third decade of life. It affects males and females in roughly equal numbers and is usually sporadic, although a subset of cases cluster in families and involve identifiable gene variants.
Because the hallmark of CVID is recurrent sinopulmonary infection rather than a single dramatic event, diagnosis is frequently delayed by years. Early recognition allows immunoglobulin replacement and proactive surveillance for the autoimmune, gastrointestinal, and lymphoproliferative complications that drive much of the long-term disease burden.
Types and Variants
CVID is not a single disease but a syndrome with several overlapping clinical phenotypes that influence monitoring and management.
Symptoms and Signs
Symptoms reflect both the antibody deficiency itself and the secondary complications that can develop over time.
Causes and Risk Factors
Most CVID arises from a combination of genetic susceptibility and impaired B-cell maturation, though a definitive single cause is identified in only a minority of cases.
Diagnosis and Investigations
Diagnosis combines a history of recurrent infection with laboratory confirmation of low immunoglobulins and poor functional antibody responses, after excluding secondary causes.
Disease Severity and Phenotype Classification
CVID is not staged like a cancer; instead, clinicians classify disease by predominant phenotype and complication burden, which guides monitoring intensity.
Standard Treatment Options
Treatment centers on replacing missing antibody function while proactively managing the complications that distinguish CVID from simple antibody deficiency.
Advanced and Emerging Treatment Options
Beyond standard immunoglobulin replacement, several targeted approaches are used for patients with refractory or complicated disease.
Biologic Therapy
Rituximab (anti-CD20)
Used for refractory autoimmune cytopenias or certain lymphoproliferative complications by depleting B-cells.
Targeted Immunomodulation
Abatacept (CTLA4-Ig)
Investigated for GLILD and granulomatous disease by modulating T-cell costimulation.
Precision Medicine
Gene-informed management
Identification of a monogenic cause (e.g., NFKB1) can guide prognosis discussions and, in select centers, targeted trial enrollment.
Cellular Therapy
Hematopoietic stem cell transplant
Reserved for select severe, treatment-refractory cases with significant immune dysregulation, evaluated case by case.
Biomarkers and Precision Medicine
Laboratory and genetic markers help confirm the diagnosis, classify phenotype, and anticipate complications.
When a Second Opinion May Be Important
Several scenarios in CVID benefit from specialist immunology re-evaluation, particularly when the diagnosis or treatment plan is uncertain.
Clinical Trials and Research
Prognosis and Key Outcome Factors
With consistent immunoglobulin replacement and proactive monitoring, many people with CVID lead long, active lives; outcomes are most influenced by the presence and control of non-infectious complications rather than the antibody deficiency alone.
Supportive Care and Living With CVID
Living well with CVID involves consistent therapy adherence alongside attention to infection prevention, nutrition, and emotional wellbeing.
How CancerFax Helps You Explore Treatment Options
CancerFax can help coordinate immunology report review, second opinions on complicated CVID phenotypes, and connections to specialist centers experienced in immunoglobulin therapy and complication management.
Get a free case reviewFrequently Asked Questions
CVID is a primary immunodeficiency in which the immune system makes too little protective antibody, leading to recurrent infections and, in many patients, additional autoimmune or gastrointestinal complications.
Recurrent sinus infections, bronchitis, or pneumonia that don't respond as expected to treatment are often the earliest clue, sometimes alongside chronic diarrhea or unusual fatigue.
A genetic cause is identified in only a minority of cases, though family clustering occurs and specific gene variants such as TACI, ICOS, and NFKB1/2 are recognized in some patients.
Diagnosis requires low immunoglobulin levels, a poor antibody response to vaccination, and exclusion of other causes of low antibodies, typically guided by an immunologist.
It is regular intravenous or subcutaneous infusion of antibody (immunoglobulin) that substitutes for the patient's own deficient antibody production, reducing infection frequency.
Yes โ autoimmune cytopenias, lung disease such as GLILD, gastrointestinal enteropathy, and an increased lymphoma risk are recognized non-infectious complications.
CVID is a lifelong condition managed with ongoing immunoglobulin replacement and complication-focused care rather than cured outright; many patients live full, active lives with treatment.
Outcomes vary widely and are influenced far more by the presence of complications such as GLILD or lymphoma than by the antibody deficiency itself; a treating immunologist can give individualized guidance.
Typical regimens involve infusions every 3โ4 weeks (intravenous) or weekly to biweekly (subcutaneous), individualized to maintain adequate trough IgG levels.
Yes. CancerFax can help coordinate review of immunology reports, facilitate second opinions for complex or refractory CVID, and connect patients with specialist centers offering advanced immunomodulatory therapy and cross-border care coordination.
Get Expert Guidance on Your CVID Care Plan
Send your immunology reports for specialist review and explore options for immunoglobulin therapy and complication management.